Home / Resources / Q1 2025 Gene, Cell, + RNA Therapy Landscape Report
Q1 2025 Gene, Cell, + RNA Therapy Landscape Report

This report, by Citeline and the American Society of Gene & Cell Therapy (ASGCT), reveals that companies in Q1 2025 announced 90 deals in financing, alliances, and acquisitions, a 20% decrease from 113 in the previous quarter.

Download the report to discover more.

''
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.
Related products
Getting the full drug RandD landscape
Pharmaprojects
世界的な医薬品研究開発の状況を追跡し、分析するための業界標準
Surfacing insights for a successful clinical trial
Trialtrove
臨床試験の戦略、設計、実施のための頼りになる情報リソース
Building a data driven site and investigator selection model
Sitetrove
グローバルな臨床試験の治験責任医師と治験実施施設の情報を提供する、業界をリードするスイート

Related resources

CGT Development Is Booming_resource-card-thumbnail
NOV 22, 2023
Article
商業化支援サービス

CGT Development Is Booming, but Manufacturing Workforce Must Keep Up

Due to unprecedented growth in the development of cell and gene therapies, there is high demand for certain workforce roles.

Clinical-resource-ISCT Report_resource-card-thumbnail
JUN 01, 2023
Report
Clinical

Cell and Gene Therapy Global Regulatory Report

The first Cell and Gene Therapy Regulatory Report from Citeline and ISCT provides a global overview of the cell and gene therapy landscape.

Gene, Cell, & RNA Therapy Landscape Report cover
MAR 28, 2025
Report
商業化支援サービス

Q4 2024 Gene, Cell, + RNA Therapy Landscape Report

This report reaffirms the expanding horizons of molecular medicine.

View all